ÐǺ£ÆåÅÆ’s 25th Anniversary

From Where We Started to Where We are Going

February 25, 2024 marked ÐǺ£ÆåÅÆ’s 25th anniversary.

Over the past quarter-century, ÐǺ£ÆåÅÆ has emerged as a scientific leader in antibody research, working towards the goal of pioneering and revolutionizing the way we treat cancer and other serious diseases.

We are extra[not]ordinary®


Powered by our extra[not]ordinary teams, we continue to break new grounds in antibody research, translational and precision medicine, and data sciences.​
​
Since our founding in 1999, innovative science has been our core, as we strive to create medicines that have never been made before for patients with limited treatment options facing cancer and other serious diseases.
Today, our innovations power eight approved antibody-based medicines and our workforce has grown from 10 to 2,100+ people internationally.​

Staying true to our history, patients continue to guide every decision we make. Each and every one of us, regardless of where we sit in the organization is driven by our core purposes – that our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics.​

Today, we are proud to be building on this legacy, as we evolve into a fully integrated biotech innovation powerhouse.

25 years of innovation

ÐǺ£ÆåÅÆ CEO Jan van de Winkel reflects on 25 years of innovation in cancer treatment and how we are driven by our vision of delivering breakthrough antibody medicines for people with cancer and other serious diseases.

A history of accomplishments rooted in science

It is our aspiration for the future that by 2030, our knock-your-socks-off antibody medicines (KYSO antibody medicines®) are fundamentally transforming the lives of people with cancer and other serious diseases. We strive to achieve this goal by working together as one team and building on our world-class research in antibodies to expand our capabilities beyond the lab.